KEITH A WEBSTER
Paramedic at Jefferson St, Miami, FL
License number
Florida 200596
Issued Date
Sep 8, 2000
Effective Date
Dec 5, 2014
Expiration Date
Dec 1, 2018
Category
Health Care
Type
Paramedic
Address
Address
3425 Jefferson St, Miami, FL 33133
Personal information
See more information about KEITH A WEBSTER at radaris.comName
Address
Phone
53 Quiet Cv, Freeport, FL 32439
413 Ocean Grove Cir, Saint Augustine, FL 32080
907 S Maryland Ave, Plant City, FL 33563
15131 SW 128Th Ave, Miami, FL 33186
PO Box 2911, Haines City, FL 33845
Professional information
See more information about KEITH A WEBSTER at trustoria.com
Professor Of Pharmacology At University Of Miami
Professor Of Pharmacology At University Of Miami
Position:
Founder and President at Integene International LLC, Director at VBI, Professor of Pharmacology at University of Miami, Professor at University of Miami
Location:
Miami/Fort Lauderdale Area
Industry:
Biotechnology
Work:
Integene International LLC
since Jun 2009
-
Founder and President
VBI
since Jun 2004
-
Director
University of Miami
since Sep 2003
-
Professor of Pharmacology
University of Miami
since Sep 1995
-
Professor
Miami Cardiovascular Innovations
Jun 2008 - Jun 2009
-
Founder, CSO
Education:
University of York 1974 - 1981
PH.D., Biochemistry
PH.D., Biochemistry
Languages:
French, Middle (ca.1400-1600)
Agent At Remax
Agent At Remax
Position:
agent at remax
Location:
Miami/Fort Lauderdale Area
Industry:
Real Estate
Work:
remax
-
agent
Agent At Remax
Agent At Remax
Position:
agent at remax
Location:
Miami/Fort Lauderdale Area
Industry:
Real Estate
Work:
remax
-
agent
Compositions, Cells, Kits And Methods For Autologous Stem Cell Therapy
Compositions, Cells, Kits And Methods For Autologous Stem Cell Therapy
US Patent:
2013030, Nov 14, 2013
Filed:
Nov 11, 2011
Appl. No.:
13/884054
Inventors:
Keith A. Webster - Key Biscayne FL, US
International Classification:
C12N 15/85, A61K 35/28, C12N 15/86
US Classification:
424 9321, 435325, 435366
Abstract:
Described herein are compositions, kits and methods for stimulating angiogenic functions of stem cells and/or progenitor cells having pro-angiogenic potential (e.g., endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs)) before transplantation (e.g., ex vivo cell therapy) based on the discovery that functional recovery of CD34+ cells from coronary artery disease (CAD) patients is improved by transfection of antagomirs against one or more miRs of a plurality of miRs identified to be over-expressed in cells from CAD patients. Described herein are methods to recover the functions of EPCs isolated from patients with cardiovascular disease (e.g., CAD or peripheral artery disease (PAD)) by bioengineering the cells with antagomirs and/or premirs to specific micro-RNAs. The bioengineered cells can then be used to treat patients with ischemic or ischemic-related disease (e.g., CAD or PAD) by autologous stem cell therapy.
Molecular Switch For Regulating Mammalian Gene Expression
Molecular Switch For Regulating Mammalian Gene Expression
US Patent:
2005026, Dec 1, 2005
Filed:
Apr 29, 2005
Appl. No.:
11/118963
Inventors:
Keith Webster - Key Biscayne FL, US
International Classification:
C12P021/06, C12N015/09
US Classification:
435320100, 435455000
Abstract:
Expression vectors are disclosed that are comprised of (a) one or more silencer elements and conditionally inducible elements to form silencer-inducible regions and (b) promoters in operative linkage upstream of at least one expressed region. The expression vector thereby regulates expression of at least one downstream region by conditional silencing in which an expressed DNA region of a gene is transcribed to produce RNA transcripts, which may or may not be translated to produce polypeptides. Genetically engineered mammalian cells and non-human mammals can be made using such expression vectors through transfection and transgenic techniques. Moreover, processes of making and using the aforementioned products are disclosed (e.g., the expression vector may be used diagnostically, therapeutically, or prophylactically).
Hypoxia Regulated Conditionally Silenced Aav Expressing Angiogenic Inducers
Hypoxia Regulated Conditionally Silenced Aav Expressing Angiogenic Inducers
US Patent:
2013013, May 23, 2013
Filed:
Nov 1, 2010
Appl. No.:
13/504438
Inventors:
Keith A. Webster - Key Biscayne FL, US
Assignee:
UNIVERSITY OF MIAMI - Miami FL
International Classification:
A61K 31/7088
US Classification:
514 44 R, 4353201
Abstract:
Methods and compositions for the treatment of hypoxia associated disorders by directional angiogenesis/arteriogenesis. Conditionally silenced vectors expressing a therapeutic molecule under hypoxic conditions avoid chaotic vascularization and allow for the orderly growth of new vessels into damaged tissue.
Methods, Compositions, Cells, And Kits For Treating Ischemic Injury
Methods, Compositions, Cells, And Kits For Treating Ischemic Injury
US Patent:
2013023, Sep 12, 2013
Filed:
Nov 10, 2011
Appl. No.:
13/884057
Inventors:
Keith A. Webster - Key Biscayne FL, US
International Classification:
A61K 35/28, A61K 31/7088, A61K 35/12
US Classification:
424 937
Abstract:
The methods, compositions, cells and kits described herein are based on the discovery that stem cells, when injected into ischemic tissue of mammals, can be protected by preconditioning of the ischemic tissue with hypoxia-regulated human VEGF and human IGF-1. Methods, compositions, cells and kits for treating tissue injured by ischemia or at risk of ischemic injury in a subject are thus described herein.
Molecular Switch For Regulating Mammalian Gene Expression
Molecular Switch For Regulating Mammalian Gene Expression
US Patent:
6893867, May 17, 2005
Filed:
Nov 28, 2000
Appl. No.:
09/723326
Inventors:
Keith A. Webster - Key Biscayne FL, US
International Classification:
C12N015/63
US Classification:
4353201
Abstract:
Expression vectors are disclosed that are comprised of (a) one or more silencer elements and conditionally inducible elements to form silencer-inducible regions and (b) promoters in operative linkage upstream of at least one expressed region. The expression vector thereby regulates expression of at least one downstream region by conditional silencing in which an expressed DNA region of a gene is transcribed to produce RNA transcripts, which may or may not be translated to produce polypeptides. Genetically engineered mammalian cells and non-human mammals can be made using such expression vectors through transfection and transgenesis techniques. Moreover, processes of making and using the aforementioned products are disclosed (e. g. , the expression vector may be used diagnostically, therapeutically, or prophylactically).
Preventing Ischemia-Induced Cell Damage
Preventing Ischemia-Induced Cell Damage
US Patent:
2004015, Aug 5, 2004
Filed:
Jul 22, 2003
Appl. No.:
10/624880
Inventors:
Keith Webster - Key Biscayne FL, US
International Classification:
A61K048/00, C12N005/02
US Classification:
514/044000, 435/375000
Abstract:
Hypoxia-acidosis-associated cell death is mediated by BNIP3, a member of the Bcl-2 family of apoptosis-regulating proteins. Chronic hypoxia induced the expression and accumulation of BNIP3 mRNA and protein in cardiac myocytes but acidosis was required to activate the death pathway. Acidosis stabilized BNIP3 protein and increased the association with mitochondria. Cell death by hypoxia-acidosis was blocked by pretreatment with antisense BNIP3 oligonucleotides. The pathway included extensive DNA fragmentation and opening of the mitochondrial permeability transition pore but no apparent caspase activation. Overexpression of wild type BNIP3, but not a translocation-defective mutant activated cardiac myocyte death when the myocytes were acidotic or hypoxic.